Community Trial of a Comprehensive Psychosocial Treatment for HFASDs / Christopher LOPATA in Focus on Autism and Other Developmental Disabilities, 30-2 (June 2015)  

Public ISBD [article]  inFocus on Autism and Other Developmental Disabilities > 30-2 (June 2015) . - p.115-125 Titre : Community Trial of a Comprehensive Psychosocial Treatment for HFASDs Type de document : Texte imprimé et/ou numérique Auteurs : Christopher LOPATA, Auteur ; Jennifer A. TOOMEY, Auteur ; Marcus L. THOMEER, Auteur ; Christin A. MCDONALD, Auteur ; Jeffery D. FOX, Auteur ; Rachael A. SMITH, Auteur ; David L. MEICHENBAUM, Auteur ; Martin A. VOLKER, Auteur ; Gloria K. LEE, Auteur ; Alanna M. LIPINSKI, Auteur Article en page(s) : p.115-125 Langues : Anglais (eng) Mots-clés : community effectiveness trial  manualized treatment  community replication  comprehensive psychosocial intervention  high-functioning autism spectrum disorders Index. décimale : PER Périodiques Résumé : This community effectiveness trial examined the feasibility and efficacy of a comprehensive psychosocial treatment for 28 children, aged 7 to 10 years with high-functioning autism spectrum disorders (HFASDs). Treatment included instruction and therapeutic activities targeting social skills, face-emotion recognition skills, interest expansion, and interpretation of non-literal language skills. A behavioral program was instituted to foster skills acquisition and reduce ASD symptoms and problem behaviors. Feasibility was supported in high levels of fidelity and satisfaction. Significant improvements were found for the children’s non-literal language skills and parent ratings of target social and communicative skills, broader social performance, and ASD symptoms. Secondary staff ratings corroborated parent ratings. Results suggest that the treatment, when administered by a community agency, was feasible and yielded positive outcomes similar to prior randomized clinical trials (RCTs). En ligne : http://dx.doi.org/10.1177/1088357614525662 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=257 [article] Community Trial of a Comprehensive Psychosocial Treatment for HFASDs [Texte imprimé et/ou numérique] / Christopher LOPATA, Auteur ; Jennifer A. TOOMEY, Auteur ; Marcus L. THOMEER, Auteur ; Christin A. MCDONALD, Auteur ; Jeffery D. FOX, Auteur ; Rachael A. SMITH, Auteur ; David L. MEICHENBAUM, Auteur ; Martin A. VOLKER, Auteur ; Gloria K. LEE, Auteur ; Alanna M. LIPINSKI, Auteur . - p.115-125. Langues : Anglais (eng) in Focus on Autism and Other Developmental Disabilities > 30-2 (June 2015) . - p.115-125 Mots-clés : community effectiveness trial  manualized treatment  community replication  comprehensive psychosocial intervention  high-functioning autism spectrum disorders Index. décimale : PER Périodiques Résumé : This community effectiveness trial examined the feasibility and efficacy of a comprehensive psychosocial treatment for 28 children, aged 7 to 10 years with high-functioning autism spectrum disorders (HFASDs). Treatment included instruction and therapeutic activities targeting social skills, face-emotion recognition skills, interest expansion, and interpretation of non-literal language skills. A behavioral program was instituted to foster skills acquisition and reduce ASD symptoms and problem behaviors. Feasibility was supported in high levels of fidelity and satisfaction. Significant improvements were found for the children’s non-literal language skills and parent ratings of target social and communicative skills, broader social performance, and ASD symptoms. Secondary staff ratings corroborated parent ratings. Results suggest that the treatment, when administered by a community agency, was feasible and yielded positive outcomes similar to prior randomized clinical trials (RCTs). En ligne : http://dx.doi.org/10.1177/1088357614525662 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=257

Prevalence and Predictors of Psychotropic Use in Children with High-Functioning ASDs / Christopher LOPATA in Autism Research and Treatment, (May 2013)  

Public ISBD [article]  inAutism Research and Treatment > (May 2013) . - 6 p. Titre : Prevalence and Predictors of Psychotropic Use in Children with High-Functioning ASDs Type de document : Texte imprimé et/ou numérique Auteurs : Christopher LOPATA, Auteur ; Jennifer A. TOOMEY, Auteur ; Jeffery D. FOX, Auteur ; Marcus L. THOMEER, Auteur ; Martin A. VOLKER, Auteur ; Gloria K. LEE, Auteur Année de publication : 2013 Article en page(s) : 6 p. Langues : Anglais (eng) Index. décimale : PER Périodiques Résumé : This study examined (1) the prevalence of psychotropic medication use for a sample of children with high-functioning autism spectrum disorders (HFASDs), (2) the extent to which psychotropic agents were linked to targeted symptoms, and (3) predictors of psychotropic use. A total of 115 children, ages 6–13, with HFASDs who were enrolled in psychosocial treatment trials were included in this study. Parents completed extensive background and rating forms prior to treatment that included data on demographic characteristics, child health, child medication use, and child ASD-related symptoms. Results indicated that 33% ( ) of the sample was taking psychotropic medication with the most common being stimulants (25%; ), antidepressants (10%; ), and neuroleptics (6%; ). All children taking stimulants had target symptoms that were appropriate for stimulant medication, whereas 57% of those taking neuroleptics and 42% of those taking antidepressants did not have targeted symptoms consistent with the medication. Logistic regression for the major psychotropic drug categories indicated that lower IQ was a significant predictor of increased antidepressant and neuroleptic use. A higher level of ASD-related symptoms was related to the likelihood of stimulant use. En ligne : http://dx.doi.org/10.1155/2013/384527 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=201 [article] Prevalence and Predictors of Psychotropic Use in Children with High-Functioning ASDs [Texte imprimé et/ou numérique] / Christopher LOPATA, Auteur ; Jennifer A. TOOMEY, Auteur ; Jeffery D. FOX, Auteur ; Marcus L. THOMEER, Auteur ; Martin A. VOLKER, Auteur ; Gloria K. LEE, Auteur . - 2013 . - 6 p. Langues : Anglais (eng) in Autism Research and Treatment > (May 2013) . - 6 p. Index. décimale : PER Périodiques Résumé : This study examined (1) the prevalence of psychotropic medication use for a sample of children with high-functioning autism spectrum disorders (HFASDs), (2) the extent to which psychotropic agents were linked to targeted symptoms, and (3) predictors of psychotropic use. A total of 115 children, ages 6–13, with HFASDs who were enrolled in psychosocial treatment trials were included in this study. Parents completed extensive background and rating forms prior to treatment that included data on demographic characteristics, child health, child medication use, and child ASD-related symptoms. Results indicated that 33% ( ) of the sample was taking psychotropic medication with the most common being stimulants (25%; ), antidepressants (10%; ), and neuroleptics (6%; ). All children taking stimulants had target symptoms that were appropriate for stimulant medication, whereas 57% of those taking neuroleptics and 42% of those taking antidepressants did not have targeted symptoms consistent with the medication. Logistic regression for the major psychotropic drug categories indicated that lower IQ was a significant predictor of increased antidepressant and neuroleptic use. A higher level of ASD-related symptoms was related to the likelihood of stimulant use. En ligne : http://dx.doi.org/10.1155/2013/384527 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=201

---

1 (1 - 2 / 2)